Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;38(6):1139-1159.
doi: 10.1007/s10557-024-07579-9. Epub 2024 Jun 13.

Insight into Cardioprotective Effects and Mechanisms of Dexmedetomidine

Leyu Jiang #  1 , Wei Xiong #  2 , Yuqiao Yang  1 , Jinqiao Qian  3
Affiliations
Review

Insight into Cardioprotective Effects and Mechanisms of Dexmedetomidine

Leyu Jiang et al. Cardiovasc Drugs Ther. 2024 Dec.

Abstract

Purpose: Cardiovascular disease remains the leading cause of death worldwide. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist with sedative, analgesic, anxiolytic, and sympatholytic properties, and several studies have shown its possible protective effects in cardiac injury. The aim of this review is to further elucidate the underlying cardioprotective mechanisms of dexmedetomidine, thus suggesting its potential in the clinical management of cardiac injury.

Results and conclusion: Our review summarizes the findings related to the involvement of dexmedetomidine in cardiac injury and discusses the results in the light of different mechanisms. We found that numerous mechanisms may contribute to the cardioprotective effects of dexmedetomidine, including the regulation of programmed cell death, autophagy and fibrosis, alleviation of inflammatory response, endothelial dysfunction and microcirculatory derangements, improvement of mitochondrial dysregulation, hemodynamics, and arrhythmias. Dexmedetomidine may play a promising and beneficial role in the treatment of cardiovascular disease.

Keywords: Cardioprotective; Cell death; Dexmedetomidine; Myocardial ischemia-reperfusion injury; α2 adrenoreceptor agonist.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Conflicts of Interest: The authors declare that they have no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Li Z, Lin L, Wu H, et al. Global, Regional, and National Death, and Disability-Adjusted Life-Years (DALYs) for cardiovascular disease in 2017 and trends and risk analysis from 1990 to 2017 using the Global Burden of Disease Study and implications for prevention. Front Public Health. 2021;9:559751. https://doi.org/10.3389/fpubh.2021.559751 . - DOI - PubMed - PMC
    1. Afonso J, Reis F. Dexmedetomidine: current role in anesthesia and intensive care. Rev Bras Anestesiol. 2012;62(1):118–33. https://doi.org/10.1016/S0034-7094(12)70110-1 . - DOI - PubMed
    1. Brock L. Dexmedetomidine in adult patients in cardiac surgery critical care: an evidence-based review. AACN Adv Crit Care. 2019;30(3):259–68. https://doi.org/10.4037/aacnacc2019888 . - DOI - PubMed
    1. Vandemoortele O, Hannivoort LN, Vanhoorebeeck F, Struys M, Vereecke HEM. General purpose pharmacokinetic-pharmacodynamic models for target-controlled infusion of anaesthetic drugs: a narrative review. J Clin Med. 2022;11(9). https://doi.org/10.3390/jcm11092487 .
    1. Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913. https://doi.org/10.1007/s40262-017-0507-7 . - DOI - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources